U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155395) titled 'Inflammatory and Hematological Indices in Diabetic STEMI Patients Undergoing Primary PCI' on Aug. 24.
Brief Summary: ST-segment Elevation Myocardial Infarction (STEMI) remains a major cause of mortality despite the adoption of Primary Percutaneous Coronary Intervention (PPCI) as the standard treatment. However, outcomes still vary significantly among patients, especially between diabetic and non-diabetic cohorts.
The research question driving this study is: Can hematologic, inflammatory, and thrombotic indices serve as reliable prognostic tools in predicting the no-reflow phenomenon and coronary artery disease (CAD) severity in STE...